drugset / Trial / NCT00234078

Dose-response Study of OPC-12759 Ophthalmic Suspension

NCT00234078

Phase 2 Completed 290 enrolled Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.

Timeline

Start
2005-01
Primary completion
2006-04
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 0.5 %
Subject Rebamipide Small molecule 1 %
Subject Rebamipide Small molecule 2 %

Indications